Background Some patients with progressive supranuclear palsy syndrome (PSPS)
demonstrate a focal area of midbrain hypometabolism on FDG-PET scans which we call the …

Background and purpose Midbrain atrophy is a characteristic feature of progressive
supranuclear palsy (PSP), although it is unclear whether it is associated with the PSP …

Objectives–To assess midbrain atrophy through morphometric (linear, surface and
volumetric) measurements in patients with clinically diagnosed progressive supranuclear …

Purpose Recently, it has been recognized that pathologically proven progressive
supranuclear palsy (PSP) cases are classified into various clinical subtypes with non …

Background To enhance the sensitivity and specificity of the clinical diagnosis of progressive
supranuclear palsy (PSP), neuroradiological parameters established in pathologically …

Objective Frontal hypometabolism on FDG-PET is observed in progressive supranuclear
palsy (PSP), although it is unclear whether it is a feature of all PSP clinical variants and …

Objectives: MRI-based measurements used to diagnose progressive supranuclear palsy
(PSP) typically lack pathologic verification and are not easy to use routinely. We aimed to …

Objective: To evaluate the area of the midbrain and pons on mid-sagittal MRI in patients with
progressive supranuclear palsy (PSP), Parkinson disease (PD), and multiple-system atrophy …

Because there are no biological markers for the clinical diagnosis of progressive
supranuclear palsy (PSP) and corticobasal degeneration (CBD), we established a …

The objective of this study was to determine the prevalence, incidence, and clinical
diagnostic accuracy for neuropathologically diagnosed progressive supranuclear palsy …